Market Overview:
The global erythromycin market is expected to grow at a CAGR of 3.8% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as rising prevalence of infectious diseases, increasing demand for erythromycin thiocyanate and growing awareness about the benefits of using macrolides over other antibiotics. However, stringent regulatory requirements and patent expirations are some of the major factors that are restraining the growth of this market. On the basis of type, erythromycin thiocyanate is expected to account for a major share in terms of revenue in 2018 and is projected to grow at a CAGR 4% during the forecast period from 2018-2030. This can be attributed to its high efficacy against various types bacteria and growing demand for its use as an antibiotic drug across different geographies.
Product Definition:
A macrolide antibiotic, erythromycin is used to treat a variety of bacterial infections. It is also effective against some protozoa and helminthes infections.
Erythromycin Thiocyanate:
Erythromycin thiocyanate is a medication used for the treatment of bacterial infections. It works by killing bacteria that has entered the body throught wounds or pores in the skin. Erythromycin thiocyanate also helps to prevent infection in people with weak immune systems, especially children and geriatric patients suffering from chronic diseases like HIV/AIDS and cancer.
Azithromycin:
Azithromycin is a type of erythromycin, it is used for the treatment of bacterial infections. It works by killing the bacteria that carry out infection. The drug was first manufactured in 1970 and was approved by FDA in 1971 as a prescription drug. In 1980, it became available over-the-counter (OTC) and has remained so ever since.
Application Insights:
The global market is segmented by application into human and veterinary medication. The human application segment dominated the overall market in terms of revenue in 2017, owing to the high usage of erythromycin for treating various bacterial infections among humans. In addition, growing use of erythromycin for preventing diseases such as chlamydia and respiratory tract infections among children is expected to drive growth over the forecast period.
In terms of revenue, veterinary applications are anticipated to grow at a CAGR similar to that observed for human medicine during the forecast period owing to increased usage of erythromycin-based products for treatment and prevention purposes among animals including dogs, cats & horses. Growing awareness about preventive measures against infectious diseases caused by bacteria is also likely fuel demand globally over next eight years.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to witness a CAGR of XX% over the forecast period, owing to increasing erythromycin consumption by human and animal health sectors in U.S., Canada, and Mexico coupled with rising awareness about antibiotic-resistant infections among patients.
Asia Pacific is anticipated to be the fastest growing regional market during the forecast period due to rapidly expanding pharmaceutical industry along with improving healthcare facilities leading to increased adoption of antibiotics especially erythromycin thiocyanate tablets for treating various infectious diseases such as tuberculosis (TB), bacterial pneumonia, traveler's diarrhea etc.
Growth Factors:
- Increasing prevalence of bacterial infections: The increasing prevalence of bacterial infections is one of the key growth drivers for the erythromycin market. This is because erythromycin is an effective antibiotic against a wide range of bacteria.
- Rising demand for generics: The high cost of branded drugs has led to an increase in the demand for generics, which are cheaper alternatives. Erythromycin is available as a generic drug and this will help to fuel its growth in the coming years.
- Growing use in pediatric patients: Erythromycin is increasingly being used in pediatric patients owing to its safety and efficacy profile. This will help to drive its growth in the coming years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Erythromycin Market Research Report
By Type
Erythromycin Thiocyanate, Azithromycin, Clarithromycin, Roxithromycin, Others
By Application
Human Medication, Veterinary Medication
By Companies
Kelun Chuanning Biotechnology, Ercros S.A., HEC Group, Envee Drugs Pvt Ltd, Mehta Api, Abbvie, Ningxia Qiyuan, Calyx C & P, Alembic Pharma, SM Biomed, Anuh Pharma, Shaoxing Hantai Pharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
246
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Erythromycin Market Report Segments:
The global Erythromycin market is segmented on the basis of:
Types
Erythromycin Thiocyanate, Azithromycin, Clarithromycin, Roxithromycin, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Human Medication, Veterinary Medication
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Kelun Chuanning Biotechnology
- Ercros S.A.
- HEC Group
- Envee Drugs Pvt Ltd
- Mehta Api
- Abbvie
- Ningxia Qiyuan
- Calyx C & P
- Alembic Pharma
- SM Biomed
- Anuh Pharma
- Shaoxing Hantai Pharma
Highlights of The Erythromycin Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Erythromycin Thiocyanate
- Azithromycin
- Clarithromycin
- Roxithromycin
- Others
- By Application:
- Human Medication
- Veterinary Medication
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Erythromycin Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Erythromycin is a antibiotic that fights infection. It is used to treat a variety of infections, including bronchitis, pneumonia, and otitis media (ear infection). Erythromycin may also be used to treat other conditions as determined by your doctor.
Some of the key players operating in the erythromycin market are Kelun Chuanning Biotechnology, Ercros S.A., HEC Group, Envee Drugs Pvt Ltd, Mehta Api, Abbvie, Ningxia Qiyuan, Calyx C & P, Alembic Pharma, SM Biomed, Anuh Pharma, Shaoxing Hantai Pharma.
The erythromycin market is expected to register a CAGR of 3.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Erythromycin Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Erythromycin Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Erythromycin Market - Supply Chain
4.5. Global Erythromycin Market Forecast
4.5.1. Erythromycin Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Erythromycin Market Size (000 Units) and Y-o-Y Growth
4.5.3. Erythromycin Market Absolute $ Opportunity
5. Global Erythromycin Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Erythromycin Market Size and Volume Forecast by Type
5.3.1. Erythromycin Thiocyanate
5.3.2. Azithromycin
5.3.3. Clarithromycin
5.3.4. Roxithromycin
5.3.5. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Erythromycin Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Erythromycin Market Size and Volume Forecast by Application
6.3.1. Human Medication
6.3.2. Veterinary Medication
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Erythromycin Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Erythromycin Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Erythromycin Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Erythromycin Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Erythromycin Demand Share Forecast, 2019-2026
9. North America Erythromycin Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Erythromycin Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Erythromycin Market Size and Volume Forecast by Application
9.4.1. Human Medication
9.4.2. Veterinary Medication
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Erythromycin Market Size and Volume Forecast by Type
9.7.1. Erythromycin Thiocyanate
9.7.2. Azithromycin
9.7.3. Clarithromycin
9.7.4. Roxithromycin
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Erythromycin Demand Share Forecast, 2019-2026
10. Latin America Erythromycin Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Erythromycin Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Erythromycin Market Size and Volume Forecast by Application
10.4.1. Human Medication
10.4.2. Veterinary Medication
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Erythromycin Market Size and Volume Forecast by Type
10.7.1. Erythromycin Thiocyanate
10.7.2. Azithromycin
10.7.3. Clarithromycin
10.7.4. Roxithromycin
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Erythromycin Demand Share Forecast, 2019-2026
11. Europe Erythromycin Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Erythromycin Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Erythromycin Market Size and Volume Forecast by Application
11.4.1. Human Medication
11.4.2. Veterinary Medication
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Erythromycin Market Size and Volume Forecast by Type
11.7.1. Erythromycin Thiocyanate
11.7.2. Azithromycin
11.7.3. Clarithromycin
11.7.4. Roxithromycin
11.7.5. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Erythromycin Demand Share, 2019-2026
12. Asia Pacific Erythromycin Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Erythromycin Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Erythromycin Market Size and Volume Forecast by Application
12.4.1. Human Medication
12.4.2. Veterinary Medication
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Erythromycin Market Size and Volume Forecast by Type
12.7.1. Erythromycin Thiocyanate
12.7.2. Azithromycin
12.7.3. Clarithromycin
12.7.4. Roxithromycin
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Erythromycin Demand Share, 2019-2026
13. Middle East & Africa Erythromycin Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Erythromycin Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Erythromycin Market Size and Volume Forecast by Application
13.4.1. Human Medication
13.4.2. Veterinary Medication
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Erythromycin Market Size and Volume Forecast by Type
13.7.1. Erythromycin Thiocyanate
13.7.2. Azithromycin
13.7.3. Clarithromycin
13.7.4. Roxithromycin
13.7.5. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Erythromycin Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Erythromycin Market: Market Share Analysis
14.2. Erythromycin Distributors and Customers
14.3. Erythromycin Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Kelun Chuanning Biotechnology
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Ercros S.A.
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. HEC Group
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Envee Drugs Pvt Ltd
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Mehta Api
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Abbvie
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Ningxia Qiyuan
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Calyx C & P
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Alembic Pharma
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. SM Biomed
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Anuh Pharma
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Shaoxing Hantai Pharma
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
